Home > Oncology > ASCO 2022 > Spectacular results for dostarlimab in mismatch repair deficient rectal cancer

Spectacular results for dostarlimab in mismatch repair deficient rectal cancer

Presented By
Dr Andrea Cercek, Memorial Sloan Kettering Cancer Center, NY, USA
Conference
ASCO 2022
A phase 2 trial, investigating neoadjuvant treatment with the PD-1 inhibitor dostarlimab in patients with stage II or III mismatch repair deficient rectal cancer showed a response rate of 100% following treatment with this agent in the thus far analysed patients. Off-protocol use of neoadjuvant immunotherapy in this population is likely to occur. “Locally advanced rectal cancer is treated with a combination of chemotherapy, radiation, and optional surgery, with all its costs and life-altering consequences,” said Dr Andrea Cercek (Memorial Sloan Kettering Cancer Center, NY, USA) [1]. Patients with mismatch repair deficient rectal cancer are relatively resistant to chemotherapy but are responsive to checkpoint inhibitors [2,3]. The current phase 2 study aimed to assess whether neoadjuvant PD-1 inhibition may be able to replace chemotherapy, chemo- and radiation therapy, or chemotherapy, radiation therapy, and surgery in patients with mismatch repair...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on